Open AccessEndocan: A New Molecule Playing a Role in the Development of Hypertension and Chronic Kidney Disease?
Author(s) -
Afsar Baris,
Takir Mumtaz,
Kostek Osman,
Covic Adrian,
Kanbay Mehmet
Publication year - 2014
Publication title -
the journal of clinical hypertension
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.909
H-Index - 67
eISSN - 1751-7176
pISSN - 1524-6175
DOI - 10.1111/jch.12440
Subject(s) - medicine , kidney disease , cell adhesion molecule , inflammation , downregulation and upregulation , kidney , secretion , cancer research , immunology , bioinformatics , gene , biochemistry , chemistry , biology
Recently, endocan—formerly known as endothelial cell‐specific molecule 1 ( ESM ‐1)—was found to be associated with entities such as cancer, hypertension, renal transplant rejection, and chronic renal failure. Endothelial cells of many organs secrete endocan, but the exact functions of this relatively new molecule have not been elucidated completely. Emerging evidence suggests, however, that endocan plays an important role in inflammation, upregulation of cell adhesion molecules, lymphocyte functions, and endothelial cytoskeleton rearrangement. As suggested above, endocan has a prognostic impact in hypertension, transplant rejection, and chronic renal failure. In the current review, the evidence regarding endocan, hypertension, and chronic renal failure are summarized.